HRP20201432T1 - Il-17a sredstvo za vezivanje i njegove uporabe - Google Patents
Il-17a sredstvo za vezivanje i njegove uporabe Download PDFInfo
- Publication number
- HRP20201432T1 HRP20201432T1 HRP20201432TT HRP20201432T HRP20201432T1 HR P20201432 T1 HRP20201432 T1 HR P20201432T1 HR P20201432T T HRP20201432T T HR P20201432TT HR P20201432 T HRP20201432 T HR P20201432T HR P20201432 T1 HRP20201432 T1 HR P20201432T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- antigen
- binding
- binding fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
Claims (7)
1. Protutijelo koje veže IL-17A ili njegov fragment koji veže antigen, koje sadrži:
varijabilna regija lakog lanca protutijela, koji sadrži LCDR1, LCDR2 i LCDR3 kao što je prikazano u SEQ ID NO: 13, SEQ ID NO: 14, i SEQ ID NO: 15 odnosno; i
varijabilna regija teškog lanca protutijela, koja sadrži HCDR1, HCDR2 i HCDR3 kao što je prikazano u SEQ ID NO: 10, SEQ ID NO: 11, i SEQ ID NO: 12, odnosno;
naznačeno time da je varijabilna regija teškog lanca protutijela odabrana od varijabilne regije teškog lanca prikazane u SEQ ID NO: 5, SEQ ID NO: 6 i SEQ ID NO: 7;
i naznačeno time da varijabilna regija lakog lanca protutijela je odabrana između varijabilne regije lakog lanca u SEQ ID NO: 9.
2. Protutijelo koje veže IL-17A ili njegov fragment koji veže antigen sukladno patentnom zahtjevu 1, koje dodatno sadrži konstantnu regiju lakog lanca izvedena iz ljudskog κ lanca, ili konstantnu regiju lakog lanca izvedena iz ljudskog λ lanca.
3. Protutijelo koje veže IL-17A ili njegov fragment koji veže antigen sukladno patentnom zahtjevu 1 ili 2, koje dodatno sadrži konstantnu regiju lakog lanca izvedenu iz ljudskog IgG1, konstantnu regiju teškog lanca izvedenu iz ljudskog IgG2, konstantnu regiju teškog lanca izvedenu iz ljudskog IgG3, ili konstantnu regiju teškog lanca izvedenu iz ljudskog IgG4.
4. Vektor s ekspresijom IL-17A vezivno protutijelo ili fragment koji se veže na n-vezujući fragment sukladno bilo kojem od prethodnih patentnih zahtjeva.
5. Vektor sukladno patentnom zahtjevu 4, koji sadrži nukleotid koji kodira IL-17A vezujuće protutijelo ili njegov antigen-vezujući fragment sukladno bilo kojem od prethodnih patentnih zahtjeva.
6. Farmaceutska kompozicija, koja sadrži: IL-17A vezujuće protutijelo ili njegov antigen-vezujući fragment sukladno bilo kojem od prethodnih patentnih zahtjeva 1-3; i farmaceutski prihvatljiv ekscipijens, otapalo ili nosač.
7. Protutijelo koje veže IL-17A ili njegov fragment koji veže antigen sukladno bilo kojem od zahtjeva 1-3, ili farmaceutski pripravak prema zahtjevu 6, naznačeno time, da se koristi u liječenju IL-17 uzrokovanih upalnih ili autoimunih bolesti; pri čemu se bolest bira između psorijaze, psorijatičnog artritisa, ankilozirajućeg spondilitisa, multiple skleroze ili upalnog artritisa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310580942 | 2013-11-18 | ||
| PCT/CN2014/089542 WO2015070697A1 (zh) | 2013-11-18 | 2014-10-27 | Il-17a结合物及其用途 |
| EP14862443.0A EP3072905B1 (en) | 2013-11-18 | 2014-10-27 | Il-17a binding agent and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201432T1 true HRP20201432T1 (hr) | 2020-12-11 |
Family
ID=53056748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201432TT HRP20201432T1 (hr) | 2013-11-18 | 2014-10-27 | Il-17a sredstvo za vezivanje i njegove uporabe |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9862765B2 (hr) |
| EP (2) | EP3072905B1 (hr) |
| JP (1) | JP6513657B2 (hr) |
| KR (1) | KR102278487B1 (hr) |
| CN (1) | CN104936981B (hr) |
| AU (1) | AU2014350758B2 (hr) |
| CA (1) | CA2929662C (hr) |
| CY (1) | CY1123493T1 (hr) |
| ES (1) | ES2818074T3 (hr) |
| HR (1) | HRP20201432T1 (hr) |
| HU (1) | HUE052184T2 (hr) |
| LT (1) | LT3072905T (hr) |
| MX (1) | MX375889B (hr) |
| PL (1) | PL3072905T3 (hr) |
| PT (1) | PT3072905T (hr) |
| RS (1) | RS61034B1 (hr) |
| RU (1) | RU2682046C1 (hr) |
| SI (1) | SI3072905T1 (hr) |
| TW (1) | TWI674273B (hr) |
| WO (1) | WO2015070697A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106336459B (zh) * | 2015-07-13 | 2020-12-08 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 |
| CN106474470B (zh) * | 2015-08-28 | 2020-05-22 | 江苏恒瑞医药股份有限公司 | 一种抗il-17a抗体的组合物 |
| CN107236041B (zh) * | 2016-03-29 | 2020-07-24 | 舒泰神（北京）生物制药股份有限公司 | Il-17抗体 |
| CN107488227A (zh) * | 2016-06-12 | 2017-12-19 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 |
| CN109715660A (zh) | 2016-09-14 | 2019-05-03 | 北京韩美药品有限公司 | 一种能够特异性地结合il-17a的抗体及其功能片段 |
| CN108359011B (zh) * | 2017-07-21 | 2019-06-25 | 华博生物医药技术（上海）有限公司 | 靶向于白介素17a的抗体、其制备方法和应用 |
| CN107522783B (zh) * | 2017-09-30 | 2020-07-07 | 华博生物医药技术（上海）有限公司 | 一种抗白介素17a的抗体、其制备方法和应用 |
| KR102048475B1 (ko) * | 2017-11-10 | 2019-11-26 | 주식회사 와이바이오로직스 | IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도 |
| CN111303283A (zh) | 2018-12-12 | 2020-06-19 | 上海君实生物医药科技股份有限公司 | 抗il-17a抗体及其应用 |
| KR20210122243A (ko) | 2019-01-31 | 2021-10-08 | 누맙 세러퓨틱스 아게 | ＴＮＦα 및 ＩＬ-17Ａ에 대한 특이성을 가지는 다중 특이적 항체, ＩＬ-17Ａ를 표적화하는 항체, 그리고 이의 사용 방법 |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| EP4006053A4 (en) * | 2019-07-30 | 2022-10-26 | Jiangsu Hengrui Medicine Co., Ltd. | METHOD OF TREATMENT OF AN AUTOIMMUNE DISEASE WITH AN IL-17 ANTAGONIST |
| TW202241505A (zh) * | 2021-01-04 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
| WO2022184114A1 (zh) * | 2021-03-03 | 2022-09-09 | 苏州盛迪亚生物医药有限公司 | 抗il-17抗体治疗自身免疫性疾病和炎症的方法 |
| CN115703841A (zh) * | 2021-08-10 | 2023-02-17 | 复旦大学 | 白介素17a抗体与白介素22细胞因子融合蛋白及其制备方法与用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| PL2481753T3 (pl) * | 2005-12-13 | 2018-09-28 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
| MX2009001620A (es) | 2006-08-11 | 2009-02-23 | Schering Corp | Anticuerpos para il-17a. |
| GB0620729D0 (en) * | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| JP5116842B2 (ja) * | 2007-04-27 | 2013-01-09 | ザイモジェネティクス， インコーポレイテッド | ＩＬ−１７ＡおよびＩｌ−１７Ｆの両方に結合する抗体ならびにそれを使用する方法 |
| AU2008266948B2 (en) * | 2007-06-13 | 2012-08-23 | Kirin-Amgen, Inc. | IL-17 heteromeric receptor complex |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| JP2011519911A (ja) * | 2008-05-05 | 2011-07-14 | ノヴィミュンヌ エスア | 抗ｉｌ１７ａ／ｉｌ−１７ｆ交差反応抗体及びその使用方法 |
| EP2331575B1 (en) * | 2008-09-29 | 2014-05-28 | Roche Glycart AG | Antibodies against human il 17 and uses thereof |
| RU2015132478A (ru) * | 2009-03-05 | 2015-12-10 | Эббви Инк. | Связывающие il-17 белки |
| BR112012010280B1 (pt) * | 2009-10-30 | 2020-09-24 | Janssen Biotech, Inc. | Anticorpo isolado ou fragmento do mesmo que se liga especificamente a il-17a humana, seu uso, e composição farmacêutica |
| AU2012206431B2 (en) * | 2011-01-14 | 2015-04-30 | UCB Biopharma SRL | Antibody molecules which bind IL-17A and IL-17F |
| EP2771361A1 (en) * | 2011-10-24 | 2014-09-03 | AbbVie Inc. | Bispecific immunobinders directed against tnf and il-17 |
-
2014
- 2014-10-27 MX MX2016006101A patent/MX375889B/es active IP Right Grant
- 2014-10-27 PL PL14862443T patent/PL3072905T3/pl unknown
- 2014-10-27 AU AU2014350758A patent/AU2014350758B2/en active Active
- 2014-10-27 SI SI201431656T patent/SI3072905T1/sl unknown
- 2014-10-27 LT LTEP14862443.0T patent/LT3072905T/lt unknown
- 2014-10-27 ES ES14862443T patent/ES2818074T3/es active Active
- 2014-10-27 CN CN201480003663.7A patent/CN104936981B/zh active Active
- 2014-10-27 EP EP14862443.0A patent/EP3072905B1/en active Active
- 2014-10-27 RS RS20201086A patent/RS61034B1/sr unknown
- 2014-10-27 PT PT148624430T patent/PT3072905T/pt unknown
- 2014-10-27 HU HUE14862443A patent/HUE052184T2/hu unknown
- 2014-10-27 WO PCT/CN2014/089542 patent/WO2015070697A1/zh active Application Filing
- 2014-10-27 EP EP20151513.7A patent/EP3670533A1/en active Pending
- 2014-10-27 US US15/035,550 patent/US9862765B2/en active Active
- 2014-10-27 HR HRP20201432TT patent/HRP20201432T1/hr unknown
- 2014-10-27 RU RU2016122340A patent/RU2682046C1/ru active
- 2014-10-27 CA CA2929662A patent/CA2929662C/en active Active
- 2014-10-27 JP JP2016528824A patent/JP6513657B2/ja active Active
- 2014-10-27 KR KR1020167014455A patent/KR102278487B1/ko active Active
- 2014-11-14 TW TW103139516A patent/TWI674273B/zh active
-
2020
- 2020-09-09 CY CY20201100852T patent/CY1123493T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201520228A (zh) | 2015-06-01 |
| AU2014350758A1 (en) | 2016-06-30 |
| KR20160085793A (ko) | 2016-07-18 |
| MX375889B (es) | 2025-03-06 |
| PT3072905T (pt) | 2020-09-17 |
| KR102278487B1 (ko) | 2021-07-19 |
| CA2929662A1 (en) | 2015-05-21 |
| WO2015070697A1 (zh) | 2015-05-21 |
| LT3072905T (lt) | 2020-12-10 |
| EP3072905A4 (en) | 2017-06-28 |
| PL3072905T3 (pl) | 2021-03-08 |
| MX2016006101A (es) | 2016-07-21 |
| CA2929662C (en) | 2023-05-02 |
| RU2016122340A (ru) | 2017-12-26 |
| EP3072905A1 (en) | 2016-09-28 |
| CN104936981A (zh) | 2015-09-23 |
| SI3072905T1 (sl) | 2020-12-31 |
| HUE052184T2 (hu) | 2021-12-28 |
| CY1123493T1 (el) | 2022-03-24 |
| BR112016009948A2 (pt) | 2017-12-05 |
| US9862765B2 (en) | 2018-01-09 |
| EP3072905B1 (en) | 2020-08-19 |
| CN104936981B (zh) | 2018-02-27 |
| RS61034B1 (sr) | 2020-12-31 |
| EP3670533A1 (en) | 2020-06-24 |
| ES2818074T3 (es) | 2021-04-09 |
| JP6513657B2 (ja) | 2019-05-15 |
| JP2017502924A (ja) | 2017-01-26 |
| TWI674273B (zh) | 2019-10-11 |
| HK1212993A1 (zh) | 2016-06-24 |
| US20160289321A1 (en) | 2016-10-06 |
| AU2014350758B2 (en) | 2019-07-25 |
| RU2682046C1 (ru) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201432T1 (hr) | Il-17a sredstvo za vezivanje i njegove uporabe | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| JP2020500538A5 (hr) | ||
| JP2018521691A5 (hr) | ||
| HRP20160151T1 (hr) | PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA | |
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| HRP20221471T1 (hr) | Protutijela anti-fgfr3 i postupci za njihovu uporabu | |
| HRP20211773T1 (hr) | Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| JP2015533795A5 (hr) | ||
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| HRP20191678T1 (hr) | Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
| JP2015522252A5 (hr) | ||
| ME02798B (me) | Protutijela protiv dkk-1" | |
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen |